glp-1 pipeline news Agonists Weight Loss Drugs Market Report, 2025-2030 Alarming rise in weight loss

Strategic differentiation beyond efficacy and pricing is essential as GLP-1 shifts from class-based to brand-based competition, requiring companies to refine positioning, branding (e.g., dual vs

These GLP-1 receptor agonists can be categorized as either short-acting compounds, which provide short-lived receptor activation (such as exenatide and lixisenatide) or as long-acting compounds (for example albiglutide, dulaglutide, exenatide long-acting release, and liraglutide), which activate the GLP-1 receptor continuously at their recommended dose

The reference product, Victoza, clocked ~USD 350 million in annual U.S

Let me tell you why Community Is the Story (Not the Product) Like I said BioCare didnt just host one community event at Obesity Week and call it a day